Donor-Derived CD19 CAR-T Cells Deliver Lasting Remissions in Leukemia

Donor-derived anti-CD19 CAR-T therapy produced durable complete remissions in a high-risk group of patients with B-cell acute lymphoblastic leukemia that relapsed after an allogeneic stem-cell transplant, according to a study from researchers in Changsha, China. Published in Cancer Immunology, Immunotherapy, the trial enrolled 14 patients; eight had extramedullary disease, meaning tumors outside the bone marrow (including soft tissue, lymph nodes, or the central nervous system). The researchers used allogeneic CAR-T cells rather than manufacturing each patient’s own T cells. That design may avoid the poor T-cell quality seen post-transplant, though it raises risks of rejection and donor-cell attacks. After a median follow-up of 13.8 months, 92.9% achieved complete remission, with remission durations extending beyond 50 months in the longest case.